OBJECTIVES: Canadian inflammatory bowel disease (IBD) patients treated with infliximab are predominantly managed through a nationwide case management system, named BioAdvance, providing access to care, educational tools, supplies and assistance programs. The aim of this study was to identify underlying factors that were associated with positive changes in health outcomes. METHODS: Between August 1 and September 30, 2012, a web-based survey was provided to patients currently receiving infliximab therapy within BioAdvance. The cross-sectional survey included items on demographic, disease characteristics, services usage and preference, and perception of health and work absenteeism. Patients were categorized according to health trajectories: declined in health (decliners), no improvement (non-changers), moderate improvement and large improvements (strong increasers). Multivariable multinomial logistic regression was used to determine which factors were associated with different health trajectories. RESULTS: